Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Lumacaftor Placebo
DRUG
2 trials
Sponsors
Vertex Pharmaceuticals Incorporated
Conditions
Cystic Fibrosis
Phase 1
Phase 1, QT/QTC Interval Study in Healthy Subjects
Completed
NCT01910415
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Start: 2013-06-30
End: 2014-03-31
Updated: 2014-08-11
Phase 2
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
Completed
NCT01225211
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Start: 2010-10-31
End: 2014-04-30
Updated: 2015-10-05
Related Papers
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for <i>F508del-CFTR</i>
Annals of the American Thoracic Society
2017-02-01
88 citations
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
2014-06-24
329 citations